Shares of Inflarx NV (NASDAQ:IFRX) have received an average broker rating score of 1.00 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy recommendation.
Brokers have set a twelve-month consensus target price of $33.00 for the company and are expecting that the company will post ($0.23) EPS for the current quarter, according to Zacks. Zacks has also given Inflarx an industry rank of 182 out of 265 based on the ratings given to related companies.
A number of equities analysts have weighed in on IFRX shares. JPMorgan Chase & Co. started coverage on shares of Inflarx in a report on Monday, December 4th. They issued an “overweight” rating and a $30.00 price target on the stock. Leerink Swann started coverage on shares of Inflarx in a report on Monday, December 4th. They issued an “outperform” rating and a $31.00 price target on the stock. BMO Capital Markets started coverage on shares of Inflarx in a report on Monday, December 4th. They issued an “outperform” rating and a $31.00 price target on the stock. Finally, B. Riley started coverage on shares of Inflarx in a report on Thursday, February 8th. They issued a “buy” rating and a $40.00 price target on the stock.
Shares of Inflarx (IFRX) traded up $2.54 on Wednesday, hitting $31.40. 22,700 shares of the company’s stock were exchanged, compared to its average volume of 59,698. Inflarx has a 52 week low of $14.47 and a 52 week high of $34.86.
TRADEMARK VIOLATION NOTICE: “Zacks: Inflarx NV (IFRX) Receives Average Rating of “Strong Buy” from Brokerages” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://sportsperspectives.com/2018/02/21/zacks-inflarx-nv-ifrx-receives-average-rating-of-strong-buy-from-brokerages.html.
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company’s primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.